NEW YORK – Federal prosecutors in New York have filed additional criminal charges against a pharmaceutical executive who separately was heavily criticized for raising the price of a lifesaving medication.
A new indictment filed Friday in Brooklyn says Martin Shkreli and his former attorney Evan Greebel schemed to defrauded potential investors of his former drug company Retrophin Inc., based in San Diego. They say the two allocated company stock to seven employees to conceal Shkreli’s ownership of it.
READ MORE: Hated price-hiking pharma exec Martin Shkreli gets House subpoena
Shkreli previously pleaded not guilty to charges he lost investors’ money through bad trades and looted the pharmaceutical company to pay them back.
Shkreli already was reviled because another drug company he owned raised the price of Daraprim, the only approved drug for a deadly parasitic infection, by 5,000 per cent.
His attorney says the allegations won’t change the “flawed theory” of the case. Greebel’s lawyer has no comment.